Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response

BACKGROUND: Multiple sclerosis is one of the most prevalent neurological diseases in young adults affecting over 2 million people worldwide. Alemtuzumab is a highly effective therapy in relapsing remitting MS. Alemtuzumab is a monoclonal CD52 antibody that proved its efficacy against an active compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bierhansl, Laura, Ruck, Tobias, Pfeuffer, Steffen, Gross, Catharina C., Wiendl, Heinz, Meuth, Sven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650051/
https://www.ncbi.nlm.nih.gov/pubmed/33324905
http://dx.doi.org/10.1186/s42466-019-0045-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650051/
https://www.ncbi.nlm.nih.gov/pubmed/33324905
http://dx.doi.org/10.1186/s42466-019-0045-x

Ejemplares similares